Literature DB >> 34106515

A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease.

Sakil Kulkarni1, Nadia Naz1, Hongjie Gu2, Janis M Stoll1, Michael D Thompson1,3, Brian J DeBosch1,3,4.   

Abstract

The incidence of nonalcoholic fatty liver disease (NAFLD) in children is rapidly increasing. Liver fibrosis is a poor prognostic feature that independently predicts cirrhosis. The time that intercedes the first medical encounter and biopsy is rate-limiting to multi-modal treatment. This study aimed to identify non-invasive parameters to predict advanced NAFLD and fibrosis. We conducted a single-center, retrospective 10-year analysis of 640 paediatric patients who underwent liver biopsy. 55 patients, age 3-21 years, had biopsy-confirmed NAFLD. We assessed primary outcomes, NAFLD activity score (NAS) and fibrosis scores, against non-invasive parameters by linear regression, by using binary cutoff values, and by a multivariate logistic regression fibrosis prediction model. NAS correlated with platelets and female sex. Fibrosis scores correlated with platelet counts, gamma glutamyl transferase (GGT), and ultrasound shear wave velocity. 25-hydroxy-vitamin D and GGT differentiated mild versus moderate-to-advanced fibrosis. Our multivariate logistical regression model-based scoring system predicted F2 or higher (parameters: BMI%, vitamin D, platelets, GGT), with sensitivity and specificity of 0.83 and 0.95 (area under the ROC curve, 0.944). We identify a clinical model to identify high-risk patients for expedited biopsy. Stratifying patients to abbreviate time-to-biopsy can attenuate delays in aggressive therapy for high-risk patients.
© 2021 World Obesity Federation.

Entities:  

Keywords:  fibrosis; hepatitis; liver; obesity; predictive-model; steatosis

Mesh:

Year:  2021        PMID: 34106515      PMCID: PMC8928096          DOI: 10.1111/cob.12472

Source DB:  PubMed          Journal:  Clin Obes        ISSN: 1758-8103


  55 in total

Review 1.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

2.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Authors:  Zobair M Younossi; Vlad Ratziu; Rohit Loomba; Mary Rinella; Quentin M Anstee; Zachary Goodman; Pierre Bedossa; Andreas Geier; Susanne Beckebaum; Philip N Newsome; David Sheridan; Muhammad Y Sheikh; James Trotter; Whitfield Knapple; Eric Lawitz; Manal F Abdelmalek; Kris V Kowdley; Aldo J Montano-Loza; Jerome Boursier; Philippe Mathurin; Elisabetta Bugianesi; Giuseppe Mazzella; Antonio Olveira; Helena Cortez-Pinto; Isabel Graupera; David Orr; Lise Lotte Gluud; Jean-Francois Dufour; David Shapiro; Jason Campagna; Luna Zaru; Leigh MacConell; Reshma Shringarpure; Stephen Harrison; Arun J Sanyal
Journal:  Lancet       Date:  2019-12-05       Impact factor: 79.321

3.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Authors:  Vlad Ratziu; Stephen A Harrison; Sven Francque; Pierre Bedossa; Philippe Lehert; Lawrence Serfaty; Manuel Romero-Gomez; Jérôme Boursier; Manal Abdelmalek; Steve Caldwell; Joost Drenth; Quentin M Anstee; Dean Hum; Remy Hanf; Alice Roudot; Sophie Megnien; Bart Staels; Arun Sanyal
Journal:  Gastroenterology       Date:  2016-02-11       Impact factor: 22.682

4.  The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Authors:  Sana Mansoor; Lisa Yerian; Rohit Kohli; Stavra Xanthakos; Paul Angulo; Simon Ling; Rocio Lopez; Carter-Kent Christine; Ariel E Feldstein; Naim Alkhouri
Journal:  Dig Dis Sci       Date:  2014-12-25       Impact factor: 3.199

5.  Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.

Authors:  Ju Dong Yang; Manal F Abdelmalek; Cynthia D Guy; Ryan M Gill; Joel E Lavine; Katherine Yates; Jagpal Klair; Norah A Terrault; Jeanne M Clark; Aynur Unalp-Arida; Anna Mae Diehl; Ayako Suzuki
Journal:  Clin Gastroenterol Hepatol       Date:  2016-08-12       Impact factor: 11.382

6.  Nonalcoholic fatty liver disease in severely obese adolescent and adult patients.

Authors:  Ai-Xuan L Holterman; Grace Guzman; Giamila Fantuzzi; Huaping Wang; Kristin Aigner; Allen Browne; Mark Holterman
Journal:  Obesity (Silver Spring)       Date:  2013-03       Impact factor: 5.002

7.  Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.

Authors:  Christine Carter-Kent; Lisa M Yerian; Elizabeth M Brunt; Paul Angulo; Rohit Kohli; Simon C Ling; Stavra A Xanthakos; Peter F Whitington; Phunchai Charatcharoenwitthaya; Jason Yap; Rocio Lopez; Arthur J McCullough; Ariel E Feldstein
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

Review 8.  Pathological features of fatty liver disease.

Authors:  Matthew M Yeh; Elizabeth M Brunt
Journal:  Gastroenterology       Date:  2014-08-07       Impact factor: 22.682

Review 9.  Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?

Authors:  Ryan M Kwok; Dawn M Torres; Stephen A Harrison
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

Review 10.  Nonalcoholic Fatty Liver Disease in Children.

Authors:  Jake P Mann; Luca Valenti; Eleonora Scorletti; Christopher D Byrne; Valerio Nobili
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

View more
  2 in total

1.  Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: a secondary retrospective study.

Authors:  Liling Wu; Man Zhang; Haofei Hu; Qijun Wan
Journal:  Lipids Health Dis       Date:  2021-10-25       Impact factor: 3.876

2.  Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease.

Authors:  Dieter Furthner; Christian-Heinz Anderwald; Peter Bergsten; Anders Forslund; Joel Kullberg; Håkan Ahlström; Hannes Manell; Iris Ciba; Harald Mangge; Katharina Maruszczak; Pia Koren; Sebastian Schütz; Susanne Maria Brunner; Anna Maria Schneider; Daniel Weghuber; Katharina Mörwald
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-02       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.